Prespecified secondary analysis of EMPULSE (530 patients hospitalised for heart failure): empagliflozin vs placebo gave similar benefit on the primary endpoint in de novo (win ratio 1.29, 95% CI 0.89-1.89) and decompensated chronic HF (1.39, 1.07-1.81).
Secondary analysisn = 530
Angermann et al. Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE